Brief: Heidelberg Pharma Provides Update On Phase I/IIa Clinical Trial In US
07/09/2021 06:26
Sept 7 (Reuters) - HEIDELBERG PHARMA AG HPHA.DE :
* PROVIDES UPDATE ON PHASE I/IIA CLINICAL TRIAL WITH ATAC
CANDIDATE HDP-101 IN US
* COMPATIBILITY TESTS FOR CLOSED INFUSION SYSTEM WITH
HDP-101
SUCCESSFULLY COMPLETED
* CONTRACT SIGNED WITH FIRST STUDY CENTER, MD ANDERSON
CANCER
CENTER; INITIATION OF CENTER PLANNED IN NEAR FUTURE
* SHIPPING OF STUDY MEDICATION TO US IN PREPARATION
Source text for Eikon: ID:nEQb8JQzra
Further company coverage: HPHA.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty